Sequential Gemcitabine/Docetaxel Promising in NMIBC After BCG Relapse
SAN DIEGO — The use of sequential intravesical gemcitabine and docetaxel appeared effective and well tolerated in patients with high-risk non-muscle invasive bladder cancer (NMIBC) following the failure of bacillus Calmette-Guérin (BCG) therapy, a retrospective study showed. At a median follow-up of 18 months, the 6-, 12-, and 24-month high-grade recurrence-free survival (RFS) rates among […]